First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
ASCO 2023: Highlights and analysis
ASCO 2023: Latest in PARP inhibitors in prostate cancer
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine improves PFS in N2-3 nasopharyngeal carcinoma
Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis
Dostarlimab chemo combination for primary advanced or recurrent endometrial cancer
2L triple metronomic chemo shows more efficacy in comparison to systemic therapy for head and neck cancer
Next-generation selective RET inhibitor shows initial promise with RET-altered solid tumours
Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses in multiple tumour types
PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo
Osimertinib after surgery significantly improves survival in resected EGFR-mutated NSCLC